Innate Pharma Sa (IPHA) Return on Equity ROE from the fourth quarter 2025 to fourth quarter 2024 and annually, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Innate Pharma Sa  (NASDAQ: IPHA)

Innate Pharma Sa's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Innate Pharma Sa in the fourth quarter 2025?
Due to the lack of equity, it was not possible to calculate Innate Pharma Sa's return on equity (ROE) in its fourth quarter 2025

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -55 -55 -55 -55 -55
Return On Equity (TTM) - - - -4124.3 % -560.01 %
IPHA's Total Ranking # # # # #
Equity (TTM) in Millions -24 -24 -24 -24 10
Seq. Equity Change - - - - 0 %
Seq. Net Income Change - - - - -

Back to IPHA Management Effectiveness >> IPHA's 5 Years Annual ROE >> Compare IPHA ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





IPHA Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions -24 10 58 61 120
Y / Y Equity Change - -82.98 % -4.16 % -49.6 % -31.12 %
Net Income in Millions -55 -55 -8 -65 -59
Y / Y Net Income Change - - - - -
Return On Equity - -560.01 % -14.59 % -107.3 % -49.15 %

Back to IPHA Management Effectiveness >> IPHA's 5 Years Annual ROE >> Compare IPHA ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
IPHA's' Return on Equity at Yahoo Finance
IPHA's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for IPHA's Competitors
Subscribers only: Roe for Innate Pharma Sa's Suppliers
Subscribers only: Return On Equity for IPHA's Customers




Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector ROE
Interpace Biosciences Inc   484.95 %
Glucotrack Inc   393.33 %
Silexion Therapeutics Corp  387.82 %
Lifemd Inc   360.74 %
Oncotelic Therapeutics Inc   350.26 %
Traws Pharma inc   273.56 %
Scisparc Ltd  244.10 %
Rigel Pharmaceuticals Inc  240.83 %
Icecure Medical Ltd  166.36 %
Capforce Inc   157.18 %
Advanced Biomed Inc.  142.91 %
Check Cap Ltd  120.45 %
Medpace Holdings Inc   118.82 %
Tg Therapeutics Inc   101.12 %
Eli Lilly And Company  97.61 %
Amgen Inc   96.65 %
Halozyme Therapeutics Inc   92.67 %
Earth Science Tech Inc   82.09 %
Exelixis Inc   81.25 %
Elite Pharmaceuticals Inc   80.28 %
Zevra Therapeutics Inc   74.63 %
3m Company  71.32 %
Entera Bio Ltd   70.43 %
Aurinia Pharmaceuticals Inc   70.37 %
Idexx Laboratories Inc  69.78 %
Alnylam Pharmaceuticals Inc   69.25 %
Enlivex Therapeutics Ltd  63.85 %
Dariohealth Corp   59.48 %
Nrc Health  58.51 %
Zoetis Inc   56.31 %

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.